PHARMACEUTICAL COMBINATION, COMPOSITION, AND COMBINED FORMULATION CONTAINING A GLUCOKINASE ACTIVATOR AND A KATP CHANNEL BLOCKER, METHOD FOR PRODUCTION AND APPLICATION THEREOF Russian patent published in 2022 - IPC A61K31/4155 A61K31/17 A61K31/351 A61K31/381 A61K31/426 A61K31/4439 A61K31/506 A61K9/14 A61K9/20 A61K9/48 A61P3/10 

FIELD: medicine.

SUBSTANCE: group of inventions relates to the field of medicine, namely, to endocrinology. Proposed is a hypoglycemic pharmaceutical combination containing:(a) a glucokinase activator constituting the compound HMS5552 represented by the formula, or a pharmacceutically acceptable salt thereof, b) a KATP channel blocker selected from the group consisting of glimepiride, repaglinide and pharmaceutically acceptable salts thereof, wherein the mass ratio of the glucokinase activator to the KATP channel blocker is from 400:1 to 10:1. The group of inventions also relates to a hypoglycemic pharmaceutical composition, a hypoglycemic combined formulation, a method for preventing, inhibiting, delaying or treating one or multiple metabolic disorders, an application of the hypoglycemic pharmaceutical combination.

HMS5552.

EFFECT: improved therapeutic effect and reduction in the toxic or side effects compared with a single application of each of the two agents, simultaneous release of two active ingredients with a homogeneous content, which provides a possibility of optimising the speed of dissolution of the component active ingredients, in particular, accelerating the release of the component active ingredients at the pH of the intestinal medium.

85 cl, 2 dwg, 4 tbl, 9 ex